Drug General Information
Drug ID
D0Q4AQ
Former ID
DNC010250
Drug Name
6-bromo-8-(piperazin-1-yl)imidazo[1,2-a]pyrazine
Drug Type
Small molecular drug
Indication Discovery agent Investigative [530516]
Formula
C10H12BrN5
Canonical SMILES
C1CN(CCN1)C2=NC(=CN3C2=NC=C3)Br
InChI
1S/C10H12BrN5/c11-8-7-16-6-3-13-9(16)10(14-8)15-4-1-12-2-5-15/h3,6-7,12H,1-2,4-5H2
InChIKey
XNILOZDQMHSDIZ-UHFFFAOYSA-N
PubChem Compound ID
Target and Pathway
Target(s) 5-hydroxytryptamine 2C receptor Target Info Inhibitor [530516]
KEGG Pathway Calcium signaling pathway
Neuroactive ligand-receptor interaction
Gap junction
Serotonergic synapse
Inflammatory mediator regulation of TRP channels
PANTHER Pathway 5HT2 type receptor mediated signaling pathway
Reactome Serotonin receptors
G alpha (q) signalling events
WikiPathways Serotonin Receptor 2 and ELK-SRF/GATA4 signaling
Monoamine GPCRs
GPCRs, Class A Rhodopsin-like
Gastrin-CREB signalling pathway via PKC and MAPK
GPCR ligand binding
GPCR downstream signaling
References
Ref 530516Bioorg Med Chem Lett. 2010 Jan 1;20(1):266-71. Epub 2009 Oct 30.Design and synthesis of orally-active and selective azaindane 5HT2c agonist for the treatment of obesity.
Ref 530516Bioorg Med Chem Lett. 2010 Jan 1;20(1):266-71. Epub 2009 Oct 30.Design and synthesis of orally-active and selective azaindane 5HT2c agonist for the treatment of obesity.